ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells Xiao HanXianxian DuanYue Wang Preclinical study 24 June 2021 Pages: 329 - 342
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers Katherine Marie ColeMark ClemonsSharon McGee Clinical trial 22 June 2021 Pages: 343 - 350
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer H. HelbrichM. BraunK. Haertl Clinical trial Open access 31 March 2021 Pages: 351 - 359
Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer Chaobin WangFuzhong TongShu Wang Clinical trial 24 March 2021 Pages: 361 - 368
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer Hope S. RugoEduardo J. PennellaCornelius F. Waller Clinical trial Open access 14 June 2021 Pages: 369 - 377
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study Daniel ReinhornIryna KuchukRinat Yerushalmi Clinical trial 27 March 2021 Pages: 379 - 387
The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study M. E. M. JoosenS. J. SchopA. A. Piatkowski de Grzymala Clinical trial Open access 24 May 2021 Pages: 389 - 398
Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials Ki-Yong AnFernanda Z. ArthusoKerry S. Courneya Clinical trial 29 March 2021 Pages: 399 - 407
Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation Ishita ChenAstrid M. Botty Van den BrueleLior Z. Braunstein Clinical trial 26 March 2021 Pages: 409 - 414
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging Aki MorikawaMilan GrkovskiAndrew D. Seidman Clinical trial 10 June 2021 Pages: 415 - 425
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer Madeleine B. HopsonShing LeeKevin Kalinsky Clinical trial 10 April 2021 Pages: 427 - 432
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer Emre KocaPolly Ann NiravathJenny Chee Ning Chang Clinical trial 15 April 2021 Pages: 433 - 439
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial Zijing WangJiaxuan LiuBinghe Xu Clinical trial 25 April 2021 Pages: 441 - 447
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens Beverly MoyMafalda OliveiraNancy Chan Clinical trial Open access 28 April 2021 Pages: 449 - 458
Pre-diagnosis major life stressors and breast cancer outcomes Tanmayi PaiLauren CornellLaura Vallow Clinical trial 12 April 2021 Pages: 459 - 464
Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients Georgios NteliopoulosKaren PageJacqueline A. Shaw Clinical trial Open access 07 June 2021 Pages: 465 - 476
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) Tufia C. HaddadJun HeMatthew P. Goetz Clinical trial 14 April 2021 Pages: 477 - 487
Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case–control study Wendy R. Muñoz-MontañoPaula Cabrera-GaleanaCynthia Villarreal-Garza Clinical trial 16 June 2021 Pages: 489 - 500
Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up Lucie VeronDelphine WehrerPatricia Pautier Clinical trial 23 April 2021 Pages: 501 - 509
Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated Maria Cristina LeonardiIda Rosalia ScognamiglioGiovanni Corso Clinical trial 27 April 2021 Pages: 511 - 524
Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer Diddier PradaAndrea A. BaccarelliEnrique Bargalló Epidemiology 08 March 2021 Pages: 525 - 533
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience Sumir ChawlaAlison HillKara Heelan Epidemiology 08 March 2021 Pages: 535 - 545
Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia Elizabeth BuckleyElisabeth ElderDavid Currow Epidemiology Open access 21 March 2021 Pages: 547 - 560
Management and outcomes of men diagnosed with primary breast cancer Andrew E. JohnsonSuzanne B. CoopeyRachel B. Jimenez Epidemiology 08 April 2021 Pages: 561 - 569
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry Khava I. E. IbragimovaSandra M. E. GeurtsVivianne C. G. Tjan-Heijnen Epidemiology Open access 20 March 2021 Pages: 571 - 581